CGTX - CIK 0001455365
The table below shows COGNITION THERAPEUTICS INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.54M | -$9.88M | -$7.24M | -$2.71M | -$2.99M | -$772.00K |
| Capital expenditure | - | - | - | $41.00K | $134.00K | - |
| Investing cash flow | - | - | - | -$41.00K | -$134.00K | - |
| Dividends paid | - | - | - | - | - |
COGNITION THERAPEUTICS INC reported operating cash flow of -$24.59M for fiscal year 2025. That is up 13.6% from -$28.47M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$3.43M (FY 2020) to -$24.59M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$233.00K | $1.30M | $11.99M | -$10.00K | -$91.00K | $8.96M |